GLP-1semaglutideglp-1reproductive healthfrontiers

Frontiers review flags GLP-1 use for beauty standards amid reproductive-health gaps

Authors argue incretin prescribing for cosmetic weight loss in women of reproductive age outpaces the available safety evidence.

By Maren Holt · Senior Reporter, GLP-1

Sep 14 20:00 ETSource: Frontiers in endocrinology

The wire

01A Frontiers in Endocrinology paper by de Matos, Faccini, Vianna and colleagues examines rising GLP-1 receptor agonist use driven by beauty standards and its intersection with reproductive health.
02Clinicians prescribing semaglutide and related agents to women of childbearing age face limited data on fertility, contraception interactions and pregnancy exposure.
03It is a narrative review rather than new data, so the extent of harm remains uncharacterized pending prospective pregnancy registries and outcome studies.

From the source

Beauty standards and reproductive health: increasing use of GLP-1 receptor agonists despite limited evidence
Frontiers in endocrinology · 2026 · de Matos SMS, Faccini LS, Vianna FSL et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42812212/